From the hive to the brain: synergistic potential of honeybee products with alzheimer's drugs

Basit Öğe Kaydı
dc.authorid0000-0003-4056-1673
dc.contributor.authorEl-Seedi, Hesham R.
dc.contributor.authorSalama, Suzy
dc.contributor.authorShetaia, Aya A.
dc.contributor.authorElashal, Mohamed H.
dc.contributor.authorEl-Wahed, Aida Abd
dc.contributor.authorKarav, Sercan
dc.contributor.authorSaeed, Aamer
dc.date.accessioned2026-02-03T12:03:00Z
dc.date.available2026-02-03T12:03:00Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAlzheimer's disease (AD) is the most common cause of dementia. The disease spreads over the world and has an impact on human health and welfare. The patients suffer from cognitiv disability in addition to economic and social effects. It is urgently necessary to find effective medication for cognitive decline because it appears to be a central focus of neurological and neurodegenerative illnesses. Cognitive decline is an intriguing pathophysiological state. Such underlying causes of cognitive impairment linked to neurodegeneration include oxidative damage and diminished cholinergic neurotransmission. The approved therapies for neurodegenerative diseases like AD are known to have undesirable side effects and merely offer symptomatic alleviation. Honeybee products have long been recognized for their therapeutic and health-improving properties. The antioxidant and anti-inflammatory activities of bee products and their ingredients are promising agents for AD. The current review aimed to collect and expose the different studies conducted on the neuroprotective potential of honeybee products such as bee venom and propolis or their active components chrysin, ferulic acid, and quercetin in combination with the conventional anti-AD or anti-dementia treatments such as donepezil and rivastigmine. Additionally, the active component chitosan was found to form effective nanoparticles in treating the neurodegenerative diseases in concern. Although the studies collected on this topic were few, they highlighted the potential synergistic effect of honeybee products in treating AD. In conclusion, bee products combined with donepezil and rivastigmine can be considered a potential neuroprotective agent against AD. Further studies are needed to support the preclinical studies and promote the clinical trials.
dc.description.sponsorshipDeanship of Research and Graduate Studies at King Khalid University [RGP2/540/45]
dc.description.sponsorshipThe authors extend their appreciation to the Deanship of Research and Graduate Studies at King Khalid University for their support through Large Research Project under grant number (RGP2/540/45).
dc.identifier.doi10.1007/s11011-025-01727-2
dc.identifier.issn0885-7490
dc.identifier.issn1573-7365
dc.identifier.issue8
dc.identifier.pmid41160251
dc.identifier.scopus2-s2.0-105020237630
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1007/s11011-025-01727-2
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34933
dc.identifier.volume40
dc.identifier.wosWOS:001603611400001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer/Plenum Publishers
dc.relation.ispartofMetabolic Brain Disease
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectHoneybee products
dc.subjectAnti-Alzheimer drugs
dc.subjectDonepezil
dc.subjectRivastig mine
dc.subjectNanoparticles
dc.titleFrom the hive to the brain: synergistic potential of honeybee products with alzheimer's drugs
dc.typeReview

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu